Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESCAPe: Methylprednisolone in Severe CAP
NCT01283009Phase 3Completed
- Sponsor
- VA Office of Research & Development
- Start
- Jan 2012
- Primary completion
- Jul 2016
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in community acquired pneumonia (CAP) comparing Methylprednisolone with Placebo (2 arms). Primary endpoint: All-cause 60-day mortality. Started Jan 2012; status: completed.
02
Drugs
methylprednisolone
03
Conditions
community acquired pneumonia (CAP)
Beyond the preview
Go deeper on NCT01283009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01283009.